Overview

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

Status:
Completed
Trial end date:
2018-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as after photorefractive keratectomy (PRK) surgery
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals